ALUMIS INC. (ALMS) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-13

Key Insights

Srinivas Akkaraju, a director of Alumis Inc. (ALMS), acquired 588,235 shares of the company's common stock at $17 per share through his investment funds Samsara Opportunity Fund, L.P. and Samsara BioCapital, L.P.
This insider buying activity suggests that Akkaraju is bullish on Alumis and believes the stock is undervalued at the current price.
With Akkaraju's increased ownership of over 6.3 million shares, representing a significant stake in the company, his interests are now further aligned with those of other shareholders.

Want the newest filings?

This analysis covers the filing from 2026-01-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-12

The reporting person, James B. Tananbaum, has acquired a significant stake in ALUMIS INC. (ALMS) through multiple investment funds and entities under his control.
Tananbaum has acquired a total of over 10 million shares, representing a substantial ownership position of more than 10% in the company.
The reported transactions indicate a concentration of insider buying activity, which could signal confidence in the company's future prospects.

Filed: 2026-01-12

Foresite Capital, a prominent venture capital firm, has significantly increased its stake in Alumis Inc. through multiple transactions, indicating strong confidence in the company's prospects.
The reported purchases of over 400,000 shares at $17 per share suggest Foresite Capital believes Alumis is undervalued and has significant upside potential.
Foresite Capital's position as a 10% owner and the inclusion of several of its affiliated entities as reporting persons suggests a coordinated, long-term investment strategy in Alumis.

Filed: 2026-01-12

Foresite Labs, LLC and its affiliates have significantly increased their ownership stake in ALUMIS INC. (ALMS), now holding over 10% of the company's shares.
The majority of the shares were acquired through open market purchases at $17 per share, indicating the investor group's confidence in the company's prospects.
The reporting of these transactions in a timely manner suggests that Foresite Labs and its affiliates are closely monitoring their investment in ALUMIS INC.

Other reports for ALUMIS INC.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.